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Myxosarcomas are rare malignant tumors of soft connective tissues, classified into various subtypes, including myxoid
liposarcoma, myxoid chondrosarcoma, and myxoid leiomyosarcoma. In this study, we proposed to study the demographic,
tumor characteristics, and overall survival rate and compared the treatment modalities between these cancers. Patient data
collected based on locoregional metastasis presentation of the abovementioned tumors with a cutoff study of survival
duration up to 10 years were obtained from the SEER database during 1975-2016. Our results indicated that elderly
patients and females were more in locoregional myxoid leiomyosarcoma than myxoid liposarcoma and myxoid
chondrosarcoma with locoregional metastasis. The white race represented the most patients who suffered from these
cancers than other races. The heart is the primary site for the abovementioned cancers, in addition to the female genitals
to the myxoid leiomyosarcoma. Myxoid liposarcoma and myxoid chondrosarcoma patients with locoregional metastasis
were suffering from grade II, while locoregional myxoid leiomyosarcoma patients with blank grading were due to missed
data. Surgery was the most common treatment modality in this study compared with radiotherapy and chemotherapy.
Kaplan-Meier analysis showed a significant difference in survival time between the three subtypes by using histology, and
myxoid leiomyosarcoma showed prolonged survival than others. Elderly, female, white, unknown grade, surgery, no
radiation, and no chemotherapy variables were independent factors associated with overall survival among these cancers.
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Multivariate analysis also showed significant differences in overall survival between the three tumors by histology, and myxoid
leiomyosarcoma was with a better prognosis than others. Multivariate analysis of locoregional myxoid leiomyosarcoma
showed the statistical significance of black race, grade, and radiotherapy, indicating them as independent prognostic factors
of locoregional myxoid leiomyosarcoma. We conclude that surgery was the primary treatment modality against these
cancers than radiotherapy and chemotherapy. And the locoregional myxoid leiomyosarcomas showed a better prognosis
and higher survival rate than locoregional myxoid liposarcoma and locoregional myxoid chondrosarcoma.
1. Introduction
Myxosarcomas are rare malignant tumors of soft connective
tissues [1]. Myxomatous areas indicated mucin deposition
between the tumorous cells or in their exoplasm, including
mesenchymal and epithelial cells [2]. Myxosarcoma mostly
occurs in the heart [3, 4] but also may appear in other body
locations including bone [5, 6], skin [7, 8], skeletal muscles
[9], and ocular [10] and oral [11] cavities. Myxosarcomas
are characterized histopathologically with stellate-shape and
spare-spindle cells, neoplastic undifferentiated cells, mitotic
figures, and mucoid stroma [12–14], and a low rate of myxo-
sarcoma distant metastasis has been reported [15]. Myxosar-
coma is mostly treated via surgery [16].
Myxosarcoma tumors are classified into various sub-
types, including myxoid liposarcoma, myxoid chondrosar-
coma, and myxoid leiomyosarcoma [17, 18]. Myxoid
liposarcoma is a subtype of liposarcoma with a low risk of
local recurrence than larger tumors [19]. Myxoid liposarco-
mas represent 5% of soft tissue sarcoma and 10-20% of lipo-
sarcoma [20]. However, myxoid liposarcomas may develop
metastasis in almost 10% of myxoid liposarcoma patients
and constitute 80% of the 5-year overall survival rate and
60% of the 10-year overall survival rate [21]. Myxoid chon-
drosarcomas are rare in extremities’ soft tissues with less than
3% of soft tissue sarcomas [22]. Despite the myxoid chondro-
sarcomas characterized with a high risk of local recurrence
and high spread rate of metastasis, several studies reported
a prolonged survival rate of almost 70% of 10-year overall
survival [22–24]. Myxoid leiomyosarcomas are a subtype of
leiomyosarcomas characterized as rare, aggressive, and
well-recognized uterus tumors [25]. Myxoid leiomyosarcoma
showed a poor prognosis and a worse overall survival rate of
5 years, almost 11% [26].
Directed locoregional therapy on the metastasis pattern
with additional treatment of the primary tumors may reduce
the primary tumor burden, reduce metastasis prognosis, and
improve the overall survival rate than systemic treatment to
the distant metastasis [27–29]. It is reported that primary
tumor resection could promote distant metastasis [30, 31]
while this hypothesis was drawn by recent studies and eluci-
dated clinically the role of surgery in reducing the distant
metastasis and improving the overall survival rate [32, 33].
The Surveillance, Epidemiology, and End Results (SEER)
is a comprehensive program of incidence, prognosis, and
cancer surveillance in the United States (U.S.). SEER is an
authoritative program that provides information on cancer
statistics in the U.S. to minimize the cancer prognosis on
the U.S. population. SEER is supported by the Surveillance
Research Program (SRP) in the National Cancer Institute’s
(NCI’s) Division of Cancer Control and Population Sciences
(DCCPS). Among 19 registries around the U.S., cancer data
has been collected through a coordinated system. These geo-
graphic registries reflect about 35% of the U.S. population,
which represents the entire U.S. demographics. Data collec-
tion started with a few registries in 1973 and expanded to
include more areas in the U.S. [34–36].
Myxoid liposarcomas, myxoid chondrosarcomas, and
myxoid leiomyosarcomas are rare tumors with low incidence
and survival data, so a comparison study has also been chal-
lenging to clarify. So, we proposed to study the demographic,
tumor characteristics, and overall survival rates and to com-
pare the treatment modalities between locoregional metasta-
tic myxoid liposarcomas, locoregional metastatic myxoid
chondrosarcomas, and locoregional metastatic myxoid leio-
myosarcomas during 1975-2017 in 18 registries of the United
States based on SEER database analysis.
2. Methods
2.1. Data Collection
2.1.1. Study Cohort. Patient data of myxoid liposarcoma,
myxoid chondrosarcoma, and myxoid leiomyosarcoma were
obtained from the SEER database of cases diagnosed during
1975-2016 in 18 registries of the United States [37]. All
patients were identified based on the international classifica-
tion of disease for oncology, third edition (ICD-O-3), using
codes of myxoid liposarcoma (8850-8889), myxoid chondro-
sarcoma (9180-9249), and myxoid leiomyosarcoma (8890-
8929). The data extracted from the SEER database in this
study was based only on the locoregional metastasis presen-
tation of myxoid liposarcoma, myxoid chondrosarcoma,
and myxoid leiomyosarcoma tumors. We obtained a total
number of patients of about 1398 of locoregional myxoid
liposarcoma, 356 of locoregional myxoid chondrosarcoma,
and 129 of locoregional myxoid leiomyosarcoma. Cases with
unknown or missing data are included in the descriptive and
survival analysis.
2.1.2. Study Measurement. This study’s primary measure-
ment is to identify the locoregional metastasis differences of
demographic, tumor characteristics, and survival rates
between these three rare myxoid tumors (myxoid liposar-
coma, myxoid chondrosarcoma, and myxoid leiomyosar-
coma) among 18 registries of the United States during1975-
2016. All variables included in this study are based on the
cutoff study of survival duration up to 10 years [37].
2.1.3. Variable Study. All patient data are extracted from the
SEER database. Demographic data were organized as age at
diagnosis, gender, and race. The age variable was studied in
two categories (less than 50 and greater than 50) to ease the
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analysis. The race was categorized as white, black, and others
(Asian and others). The anatomical locations were catego-
rized into six variables, including soft tissue including heart,
retroperitoneum, bones and joints, female genitals, digestive
organs, and others. Oncology study includes grading and sur-
vival analysis. The tumor grade in the SEER database was
classified into grades I, II, III, IV, and unknown. Overall sur-
vival rate analysis is performed based on the study cutoff
selection of patient data from SEER. So, all cases in this study
considered only the patients with 10-year survival (120
months). The SEER database’s treatment variables, including
surgery, radiation, and chemotherapy, were included in this
study. In surgery treatment, the patients were categorized
into two variables: whether they performed the surgery or
not (yes/no). Radiation and chemotherapy variables include
the patients who received treatment or not (yes/no) [37].
2.2. Statistical Analysis. Data analysis was performed using
SPSS software version 22 (SPSS, IBM Company, Chicago,
USA). Chi-squared tests are used to analyze the variables.
Categorical variables were analyzed as frequency and per-
centage. Ten-year overall survival was calculated using
Kaplan-Meier to estimate the survival rate with a log-rank
test. Multivariate Cox proportional hazard regression was
studied to analyze the confounding variables. p < 0:05 was
used as a significant value in the study.
3. Results
3.1. Myxoid Liposarcoma
3.1.1. Demographics. Among 1398 locoregional metastatic
patients of myxoid liposarcoma extracted from the SEER
database during 1975-2016, almost 49.1% of cases with age
less than 50 years and 50.9% of cases with age greater than
50 years were diagnosed with locoregional myxoid liposar-
coma. Myxoid liposarcomas were higher in males than
females, with almost 59.4% and 40.6% of cases, respectively.
The race variable reported that the white race of almost
82.5% was higher than black and other races of almost 9.7%
and 7.9%, respectively, in this tumor, indicating that the male
gender and white people were more vulnerable to this cancer.
The location of the myxoid liposarcoma tumors showed
higher localization of cancer in the heart, which is almost
91.5% of the reported cases compared with other sites
(Table 1).
3.1.2. Oncology Characteristics. The reported data of the
locoregional metastatic patients during 1975-2016 and
obtained from the SEER database with a total number of
1398 myxoid liposarcomas in the United States showed that
this tumor has high grading II (32.8%) versus grade I
(27.9%), grades III-IV (7.6%-8.0%), and unknown (23.7%)
indicating that locoregional metastatic patients with myxoid
liposarcomas have high grading of this tumor. The cause of
death of most cases of myxoid liposarcoma was not attrib-
uted to this tumor as reported in SEER data with almost
91.4% (Table 1).
3.1.3. Treatment. Locoregional metastatic myxoid liposar-
coma treatment data are extracted from SEER during 1975-
2016, including surgery, radiotherapy, and chemotherapy
modalities. Most of the reported cases in the SEER of locore-
gional metastatic patients with myxoid liposarcoma were
performed surgery which is almost 95.2% of the total number
of patients, and this result was similar as in the literature [38].
Radiotherapy treatments of patients with locoregional myx-
oid liposarcoma of data obtained from SEER showed no big
difference between received beam radiations versus unrec-
eived patients, almost 47.1% versus 52.9%. Meanwhile, che-
motherapy variables showed a higher data of patients who
did not receive chemotherapy which is about 89.5% com-
pared with the patients who received treatment which is
about 10.5%, and these results of treatment modality indicate
that surgery treatment modality was the most performed
treatment approach in locoregional myxoid liposarcoma
patients (Table 1).
3.2. Myxoid Chondrosarcoma
3.2.1. Demographics. The data of locoregional metastatic
patients with myxoid chondrosarcoma obtained from SEER
were 356 patients. There are almost 55.1% of cases with age
less than 50 years versus 44.9% of cases with age greater than
50 years. The sex variable of locoregional metastatic myxoid
chondrosarcomas reported that the male variable was higher
than the female variable with almost 59.8% and 40.2% of
cases, respectively. White patients were also higher than
black and other races, about 76.7%, 14.6%, and 8.7%, respec-
tively, in this tumor, indicating that this tumor mostly affects
male and white people than others. The localization of the
locoregional metastatic myxoid chondrosarcoma tumor was
higher in the heart and bones/joints, almost 64.0% and
32.3%, respectively, of the reported cases compared with
other sites (Table 1).
3.2.2. Oncology Characteristics. The data obtained from the
SEER database of locoregional metastatic patients with myx-
oid chondrosarcomas showed that this tumor has higher
grade II (32.6%) and unknown (38.8%) versus grades I, III,
and IV (13.8%, 9.8%, and 5.1%, respectively), indicating that
locoregional metastatic patients with myxoid chondrosarco-
mas exhibit high grading of this tumor. The cause of death
of most cases of locoregional metastatic myxoid chondrosar-
comas also was not attributed to this tumor as reported in
SEER data with almost 76.7% (Table 1).
3.2.3. Treatment. Most of the cases obtained from the SEER
database with locoregional metastatic myxoid chondrosarco-
mas were performed surgery with almost 89% of the patients’
total number. And data obtained of locoregional metastatic
patients with myxoid chondrosarcomas did not show a big
difference between cases that received radiotherapy or not,
almost 44.1% and 55.9%, respectively. The chemotherapy
variables showed a higher data of patients who did not
receive chemotherapy, about 82.9%, compared with the
patients who received treatment which is almost 17.1%, indi-
cating that surgery is the primary treatment modality in
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Table 1: Demographic data, tumor characteristics, and treatment modality of locoregional myxoid liposarcoma, locoregional myxoid
chondrosarcoma, and locoregional myxoid leiomyosarcoma in the Unites States based on the SEER database.
Demographic chch. Myxoid liposarcoma
Total (n = 1398)
(%)
Myxoid chondrosarcoma
Total (n = 356)
(%)
Myxoid leiomyosarcoma
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locoregional metastatic myxoid chondrosarcoma patients
than radiation and chemotherapy (Table 1).
3.3. Myxoid Leiomyosarcoma
3.3.1. Demographics. Myxoid leiomyosarcomas with locore-
gional metastatic patients were obtained from the SEER data-
base in the U.S. during 1975-2016, almost 129 cases. The age
variable showed that about 63.6% of cases diagnosed with
locoregional myxoid leiomyosarcoma were with age greater
than 50 years versus 36.4% of cases with age less than 50
years, indicating that this tumor mostly occurs in the older
population. The sex variable of locoregional myxoid leio-
myosarcoma patients reported that the female variable was
higher than the male variable with almost 82.2% and 17.8%
of cases. White patients were higher than black and other
races, almost 77.5%, 18.6%, and 3.9%, respectively, in this
tumor, indicating that the female and white people were
more vulnerable to this cancer. The myxoid leiomyosarcoma
tumors were higher localized in the female genitals and heart,
almost 57.4% and 33.3%, respectively, of the reported cases
compared with other sites (Table 1).
3.3.2. Oncology Characteristics. The tumor grading variable
of locoregional myxoid leiomyosarcoma reported cases
showed that this tumor has higher unknown grading
(40.3%) versus grades II, III, and IV (16.3%, 19.4%, and
16.3%, respectively) and less grade I (7.8%). The cause of
death of locoregional myxoid leiomyosarcoma cases of
almost 72.1% was not attributed to this tumor as reported
in SEER data (Table 1).
3.3.3. Treatment. Most of the locoregional myxoid leiomyo-
sarcoma patient’s data obtained from the SEER database
are performed surgery with almost 91.5% of the total number
of patients. And the data of patients with locoregional myx-
oid leiomyosarcoma extracted by SEER did not show a big
difference between groups receiving and not receiving radio-
therapy of almost 45.7% and 54.3%, respectively. And most
of the cases did not receive chemotherapy treatments, about
86% in this tumor (Table 1).
3.4. Survival Analysis. Kaplan-Meier analysis of overall sur-
vival showed a statistically significant difference between his-
tology subtypes of myxoid liposarcoma, myxoid
chondrosarcoma, and myxoid leiomyosarcoma of locoregio-
nal metastatic patients with log-rank p < 0:004 (Figure 1).
And locoregional metastatic myxoid leiomyosarcoma
patients showed prolonged survival (median 85 months)
compared with locoregional metastatic myxoid liposarcoma
(median 58 months) and locoregional metastatic myxoid
chondrosarcoma (median 60 months) (Figure 1). The
Kaplan-Meier study indicated that variables of age more than
50 years, female gender, white race, unknown or missed
grade, surgery resection, no radiation, and no chemotherapy
variables showed statistical significance of overall survival
Table 1: Continued.
Demographic chch. Myxoid liposarcoma
Total (n = 1398)
(%)
Myxoid chondrosarcoma
Total (n = 356)
(%)
Myxoid leiomyosarcoma























































Figure 1: Overall survival of patients with locoregional myxoid
liposarcoma, locoregional myxoid chondrosarcoma, and
locoregional myxoid leiomyosarcoma by histology via Kaplan-
Meier analysis with log-rank test and median 58 months, 60
months, and 85 months, respectively, p < 0:004.
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(Table 2). Patients older than 50 showed statistical signifi-
cance of survival with a median of 58 months of locoregional
myxoid liposarcoma, 63 months of locoregional myxoid
chondrosarcoma, and 85 months of locoregional myxoid
leiomyosarcoma with log-rank p < 0:008 (Table 2,
Figure 2), indicating that patients with locoregional myxoid
leiomyosarcoma showed prolonged survival than others.
Female patients of locoregional myxoid leiomyosarcoma
with a median of 85 months showed significantly prolonged
survival time compared with locoregional myxoid liposar-
coma and locoregional myxoid chondrosarcoma (61 months
and 54 months), p < 0:007 (Table 2, Figure 2). And white
patients also showed prolonged survival in locoregional myx-
oid leiomyosarcoma (83 months) compared with locoregio-
nal myxoid liposarcoma and locoregional myxoid
chondrosarcoma (58 months and 59 months, respectively),
p < 0:014 (Table 2, Figure 2). The tumor grade showed that
unknown or missed grading in myxoid leiomyosarcoma has
significantly higher overall survival (median 85 months)
compared with other tumors (63 and 54 median months,
respectively), suggesting the inadequate data collection and
poor follow-up of patients to their registries, p < 0:017
(Table 2, Figure 2). Among the treatment modalities, surgery
resection of myxoid leiomyosarcoma tumors in locoregional
metastatic presentation results in prolonged survival time
with a median of 84 months compared with locoregional
myxoid liposarcoma and locoregional myxoid chondrosar-
coma, p < 0:008 (Table 2, Figure 2). The locoregional myxoid
leiomyosarcoma patients who were not receiving radiother-
apy and chemotherapy showed a significant difference in
overall survival time and lived prolonged than other locore-
gional myxoid liposarcoma patients and locoregional myxoid
chondrosarcoma patients with log-rank p < 0:002 and p <
0:009, respectively (Table 2, Figure 2). Multivariate analysis
of histology subtype was also meaningful that showed a sta-
tistically significant difference of overall survival between
myxoid liposarcoma, myxoid chondrosarcoma, and myxoid
leiomyosarcoma of locoregional metastatic patients, p <
0:0001, and the locoregional myxoid leiomyosarcoma cases
reported better survival time than other cancers (Figure 3).
Based on the abovementioned results and comparing these
three tumors, we selected the locoregional myxoid leiomyo-
sarcoma to perform univariate and multivariate analyses.
And the univariate analysis of locoregional myxoid leiomyo-
sarcoma showed no statistically significant difference in over-
all survival (Table 3). Moreover, multivariate analysis showed
Table 2: Overall survival study using Kaplan-Meier analysis on locoregional myxoid liposarcoma, locoregional myxoid chondrosarcoma, and
locoregional myxoid leiomyosarcoma in the United States.
Demographic chch Myxoid liposarcoma
Total (n = 1389)
Myxoid chondrosarcoma
Total (n = 356)
Myxoid leiomyosarcoma




<50 59 54 79 0.073
>50 58 63 85 0.048
Sex
Male 57 69 85 0.227
Female 61 54 85 0.007
Race
White 58 59 83 0.014
Black 62 67 102 0.318
Other 61 71 — 0.538
Grade
Grade I 55 47 98 0.361
Grade II 59 70 70 0.226
Grade III 56 75 83 0.195
Grade IV 60 92 62 0.610
Unknown 63 54 85 0.017
Surgery
Yes 59 62 84 0.008
No 49 45 85 0.411
Radiotherapy
Yes 38 47 54 0.268
No 59 54 89 0.002
Chemotherapy
Yes 56 49 79 0.431
No 59 62 85 0.009
chch: characteristics.
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that black race, with a hazard ratio (0.363), 95% CI (0.154-
0.855), p < 0:021; grade IV with a hazard ratio (3.748), 95%
CI (1.234-11.384), p < 0:02; and radiotherapy with a hazard
ratio (0.529), 95% CI (0.302-0.926), p < 0:026 were indepen-
dent prognostic factors for locoregional myxoid leiomyosar-
coma patients according to data obtained from SEER
(Table 3).
4. Discussion
Myxosarcomas are malignant soft tissue tumors character-
ized by abundant mucus [39]. Myxosarcoma was classified
into several subtypes, including myxoid liposarcoma, myx-
oid chondrosarcoma, and myxoid leiomyosarcoma [18].
Metastasis presentation of myxoid liposarcomas, myxoid
chondrosarcomas, and myxoid leiomyosarcomas was
higher with locoregional metastasis in all three abovemen-
tioned cancers compared with distant metastasis indicating
the rare distant metastasis in these cancers, interpreting
that locoregional metastasis may provide a prolonged
overall survival rate than distant metastasis [40–43]. The
SEER database is an authorized software providing statisti-
cal information on cancers among several registries in the
































































Figure 2: Overall survival of patients with locoregional myxoid liposarcoma, locoregional myxoid chondrosarcoma, and locoregional myxoid
leiomyosarcoma via Kaplan-Meier analysis with log-rank test: (a) age more than 50 years, p < 0:008; (b) female gender, p < 0:007; (c) white
race, p < 0:014; (d) unknown grade, p < 0:017; (e) surgery resection, p < 0:008; (f) radiation (no), p < 0:002; (g) chemotherapy (no), p <
0:009.
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demographic, tumor study, and survival among patients of
locoregional myxoid liposarcoma, locoregional myxoid
chondrosarcoma, and locoregional myxoid leiomyosar-
coma in the U.S. based on data extracted from the SEER
database during 1975-2016 [37].
Our demographic analysis of locoregional myxoid leio-
myosarcomas showed that most patients were older than
50 compared with locoregional myxoid liposarcomas, and
locoregional myxoid chondrosarcoma patients were show-
ing no big difference between age variables according to
data reported by SEER, and these results are similar to
that reported in literature revealing that myxoid leiomyo-
sarcomas occurred mostly in the elderly [44–46]. Myxoid
liposarcoma and myxoid chondrosarcoma tumors with
locoregional metastasis have mostly male predilection
[44, 47, 48], and the locoregional myxoid leiomyosarcoma
tumor has commonly female predilection [49]. Our
obtained data indicated that cases of myxoid liposarcomas
and myxoid chondrosarcomas with locoregional metastasis
were mostly male patients. In contrast, locoregional myx-
oid leiomyosarcoma patients were mainly female due to
myxoid leiomyosarcoma’s histological origin, which com-
monly grows in the uterus [50]. White patients were the
most patients suffering from the abovementioned cancers
compared with other races, indicating that the white race
is more vulnerable to these cancers than other races, as
reported in several studies [51, 52]. Our data were indicat-
ing that the white race represented the most patients suf-
fering from these cancers in the U.S., according to the
SEER database. Myxosarcoma tumors can be grown in
various body locations but mostly grow in the heart [53,
54]. In this study, our analysis indicated that locoregional
myxoid liposarcoma and locoregional myxoid chondrosar-
coma tumors were primarily located in the heart and
locoregional myxoid leiomyosarcoma tumors are located
mostly in female genitals and heart too.
Oncology analysis of our data obtained from SEER
showed that locoregional myxoid liposarcoma and locoregio-
nal myxoid chondrosarcoma patients suffering from tumors
have grade II differentiation. In contrast, locoregional myx-
oid leiomyosarcoma patients with blank or unknown grading
showed a higher percentage compared with another grading,
suggesting that the higher unknown cases in locoregional
myxoid leiomyosarcomas were due to the less number of
patient data collection and poor follow-up to their registries
during that time of registration, which provides missing data
compared with other well-reported cancers; however, grades
II, III, and IV were higher in locoregional myxoid leiomyo-
sarcoma compared with grade I.
Surgery is the most common approach of treatment
modality used against myxoid liposarcomas, myxoid chon-
drosarcomas, and myxoid leiomyosarcomas compared to
radiotherapy and chemotherapy [55, 56]; interestingly, our
analysis in this study indicated that the most reported cases
of myxoid liposarcomas, myxoid chondrosarcomas, and
myxoid leiomyosarcomas with locoregional metastasis were
treated with surgery. Meanwhile, in radiotherapy modality,
our analysis did not show any statistical significance among
myxoid liposarcomas, myxoid chondrosarcomas, and myx-
oid leiomyosarcomas with locoregional metastasis. And che-
motherapy treatment against locoregional metastasis of
myxoid liposarcomas, myxoid chondrosarcomas, and myx-
oid leiomyosarcomas showed statistical significance with a
higher percentage of patients who did not receive
chemotherapy.
The overall survival rate was better for locoregional local-
ization than distant metastasis, as reported in previous stud-
ies [27, 57, 58]. Our study’s overall survival based on Kaplan-
Meier analysis showed a statistically significant difference in
survival time between patients with locoregional metastasis
of myxoid liposarcomas, myxoid chondrosarcomas, and
myxoid leiomyosarcomas by using the histology variable.
The locoregional metastasis of myxoid leiomyosarcoma
showed prolonged survival than locoregional metastatic
myxoid liposarcoma and locoregional metastatic myxoid
chondrosarcoma. Kaplan-Meier analysis indicated that age
older than 50 years, female gender, white patients, unknown
or missed grade, surgery, no radiation, and no chemotherapy
variables were independent factors associated with overall
survival among locoregional metastasis of myxoid liposarco-
mas, myxoid chondrosarcomas, and myxoid leiomyosarco-
mas. As reported in the literature, myxoid leiomyosarcomas
are associated with a worse prognosis and low overall survival
rate [26]; surprisingly, our data extracted from the SEER
database of locoregional metastatic myxoid leiomyosarcomas
reflected a better prognosis and high survival rate compared
with locoregional metastatic myxoid liposarcomas and locor-
egional metastatic myxoid chondrosarcomas, suggesting that
locoregional metastasis is accompanied with prolonged sur-





















Figure 3: Multivariate analysis of patients with locoregional myxoid
liposarcoma, locoregional myxoid chondrosarcoma, and
locoregional myxoid leiomyosarcoma using Cox hazard
proportion study.
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Meaningfully, multivariate analysis using Cox hazard pro-
portion analysis between the three subtypes of myxoid
liposarcomas, myxoid chondrosarcomas, and myxoid leio-
myosarcomas with locoregional metastasis showed also a sig-
nificant difference in the overall survival rate. However, the
locoregional myxoid leiomyosarcoma showed a better sur-
vival rate than other abovementioned subtypes, so the uni-
variate and multivariate analyses of locoregional myxoid
leiomyosarcoma had been performed, and the results of the
univariate study did not show statistical significance of over-
all survival. The multivariate analysis showed the statistical
significance of the black race, tumor grade, and radiotherapy
variables of locoregional myxoid leiomyosarcoma, indicating
that variables were independent prognostic factors of locore-
gional myxoid leiomyosarcoma based on the collected data
from the SEER database. By comparing the overall survival
of three subtypes of locoregional myxoid liposarcomas,
locoregional myxoid chondrosarcomas, and locoregional
myxoid leiomyosarcomas, the results illustrated that locore-
gional myxoid leiomyosarcomas have better prognostic and
overall survival than the other subtypes.
In conclusion, in this study, we analyzed the demographic,
oncology, and survival patterns of myxoid liposarcoma, myx-
oid chondrosarcoma, and myxoid leiomyosarcoma locore-
gional metastasis in the U.S. during 1975-2016 based on
the SEER database. Our results were similar to the literature,
indicating that white patients suffered more from myxoid
liposarcoma, myxoid chondrosarcoma, and myxoid leiomyo-
sarcoma with locoregional metastasis. The heart was the
most common organ to develop locoregional metastasis of
myxoid liposarcoma, myxoid chondrosarcoma, and myxoid
leiomyosarcoma associated with high-grade differentiations.
And surgery was the main approach of treatment modality
against these cancers than radiotherapy and chemotherapy.
The survival patterns showed that elderly, female, white
patients, unknown or missed grade, surgery, radiation, and
chemotherapy were dependent factors of overall survival
among these cancers. However, locoregional myxoid leio-
myosarcomas showed a better prognosis and better survival
rate than locoregional myxoid liposarcoma and locoregional
myxoid chondrosarcoma based on Kaplan-Meier and Cox
hazard proportion studies. Adjuvant radiation and chemo-
therapy against locoregional leiomyosarcoma based on
multicenter randomized clinical trials need further study in
the future.
Abbreviations
SEER: Surveillance, Epidemiology, and End Results
U.S: United States
SRP: Surveillance Research Program
NCI: National Cancer Institute
DCCPS: Division of Cancer Control and Population
Sciences
ICD-O-3: International classification of disease for oncol-
ogy third edition.
Table 3: Univariate and multivariate analyses on locoregional myxoid leiomyosarcoma in the United States.
Demographic chch Myxoid leiomyosarcoma
Total (n = 129)
Disease Univariate Multivariate
Hazard ratio 95% CI (lower-upper) p value Hazard ratio 95% CI (lower-upper) p value
Age (years)
<50 vs. >50 1.054 0.655-1.699 0.827 0.619 0.336-1.14 0.124
Sex
Male vs. female 0.887 0.493-1.597 0.690 1.731 0.618-4.848 0.296
Race
White Ref Ref
Black 0.764 0.399-1.462 0.416 0.363 0.154-0.855 0.021
Other 0.613 0.149-2.518 0.498 1.555 0.358-6.756 0.556
Grade
Grade I Ref Ref
Grade II 1.149 0.449-2.939 0.772 1.406 0.519-3.803 0.503
Grade III 0.901 0.360-2.256 0.824 1.068 0.410-2.786 0.892
Grade IV 1.195 0.468-3.053 0.710 3.748 1.234-11.384 0.02
Unknown 0.933 0.405-2.148 0.870 1.130 0.475-2.686 0.783
Surgery
Yes vs. no 0.881 0.320-2.425 0.806 1.431 0.360-5.681 0.611
Radiotherapy
Yes vs. no 1.593 0.993-2.557 0.053 0.529 0.302-0.926 0.026
Chemotherapy
Yes vs. no 0.971 0.435-2.169 0.943 0.740 0.292-1.873 0.525
chch: characteristics; ref: reference.
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